The health and economic burden of rare endocrine disease: Often ignored, always important.

ABSTRACT:

Background

Rare endocrine diseases (RED) often pose chronic and life-threatening challenges, yet their economic costs and societal impact remains have not been precisely quantified.

Methods

We obtained patient data from the 2018 Nationwide Inpatient Sample (NIS) and the Nationwide Readmissions Database (NRD), identifying RED patients through International Classification of Diseases, 10th revision codes. The difference of economic burden between RED patients and the control group, including hospital length of stay, hospitalisation costs, and readmission rates, was assessed using chi-square tests.

Results

We extracted 638 083 (2.98%) RED-related records from the NIS database. Compared to patients with common conditions, RED patients showed an exceedingly high burden of

SUBMITTER: Liu L 

PROVIDER: S-EPMC11626685 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature